HOUSER v. FELDMAN

CourtDistrict Court, E.D. Pennsylvania
DecidedOctober 26, 2021
Docket2:21-cv-00676
StatusUnknown

This text of HOUSER v. FELDMAN (HOUSER v. FELDMAN) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
HOUSER v. FELDMAN, (E.D. Pa. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

STEVEN HOUSER, : Plaintiff, : : v. : CIVIL ACTION NO. 21-0676 : ARTHUR FELDMAN AND TEMPLE : UNIVERSITY, : Defendants. :

MEMORANDUM OPINION This case concerns, inter alia, an investigation by Defendant Temple University (“Temple”) into alleged research misconduct by Plaintiff Steven Houser. Houser has filed a Motion for a Protective Order to either enjoin the investigation or subject it to the discovery rules of the Federal Rules of Civil Procedure. Temple’s investigation was prompted by complaints received by the Department of Health and Human Services’ Division of Investigative Oversight, Office of Research Integrity (“ORI”) through the scientific research website “PubPeer.” These complaints alleged that Houser had engaged in possible research misconduct in 15 different papers that were supported by National Institute of Health grants (“PubPeer Papers”). In September 2020, in response to the PubPeer complaints, the ORI sent a letter to Temple requesting that it, in accordance with 42 C.F.R § 93.307, “examine all of the issues to determine whether each of the allegations have merit and are credible” and advising further that “the allegations require a prompt and thorough assessment to determine whether further action is necessary.” ORI’s letter then described the process Temple must follow in undertaking its assessment of the allegations against Houser. For example, Temple is required to “take all reasonable and practical steps to obtain custody of all of the research records and evidence needed to conduct the research misconduct proceeding, . . . inventory the records and evidence, and sequester them in a secure manner.” Further, it is to “pursue diligently all significant issues and leads discovered that are determined relevant to the inquiry. . . .” In accordance with the letter, Temple commenced the investigation into the 15 papers

(“PubPeer Inquiry”). It notified Houser of the PubPeer Inquiry by email on September 25, 2020. A few months later, in January 2021, Temple instructed Houser to preserve and provide it with documents relating to the PubPeer Papers and informed him that there would be an initial discussion of the specific allegations against him once Temple reviewed the documents he provided. Houser retained counsel, provided detail on his role in nine of the challenged papers and requested that Temple clarify the scope and nature of its inquiry. Shortly thereafter, Houser filed this lawsuit. Six months later, in the midst of the discovery period in this litigation, Temple informed Houser of what it referred to as a “mandatory site-visit” scheduled as part of the PubPeer Inquiry at which Houser was expected to appear and be prepared to provide copies of research records

and discuss research spaces used and individuals involved with the PubPeer Papers. Houser then filed the present Motion to “safeguard [his] rights” and to enjoin Temple from “engaging in sweeping extra-judicial discovery” as part of its PubPeer Inquiry. Temple counters that the PubPeer Inquiry is federally directed and mandated by the ORI and that Plaintiff, through his Motion, is seeking to impede the investigation. The ORI was established by the Public Health Services Act (the “Act”) as an independent entity tasked with investigating misconduct in biomedical and behavioral research supported by federal funds. 42 U.S.C. § 289b(e). The Act devises a larger regulatory framework governing investigations of research misconduct supported by federal funds. In relevant part, the Act directs the Secretary of Health and Human Services (the “Secretary”): to promulgate regulations: (1) defining research misconduct, § 289b(a)(3)(A); (2) requiring institutions which receive federal funds for research have an administrative process to review reports of research misconduct conducted at, or sponsored by, the institution, § 289b(b)(1); and, (3) creating a

process for ORI to receive allegations and reports of research misconduct, carry out investigations and take necessary remedial action, § 289b(c). The Secretary responded to this statutory mandate by “promulgating an elaborate regulatory mosaic,” which created an intricate three-tier process by which institutions and the ORI would jointly assess allegations of research misconduct. Anversa v. Partners Healthcare Sys., Inc., 835 F.3d 167, 170 (1st Cir. 2016); 42 C.F.R. Part 93. Within this regulatory mosaic, “research misconduct” is defined as “fabrication, falsification, or plagiarism in proposing, performing, or reviewing research, or in reporting research results.” 42 C.F.R. § 93.103. A finding of research misconduct requires a showing, by a preponderance of the evidence, of “a significant departure from accepted practice of the relevant research community” that was “committed intentionally, knowingly, or recklessly.” 42

C.F.R. § 93.104. Allegations of research misconduct allegations are first reviewed at the funded institution through a two-step process. The first phase is known as an “inquiry,” which is “warranted” if, among other reasons, the allegation falls within the regulatory definition of research misconduct. 42 C.F.R. § 93.307(b). The inquiry requires an “initial review of the evidence”, which includes all research records, interviews and other necessary evidence, to determine whether the allegation warrants an investigation. 42 C.F.R. § 93.307(b)-(d). The inquiry culminates in a written report, which the researcher who is the subject of the inquiry can review and comment on. 42 C.F.R. § 93.307(f). While the institution generally “must complete the inquiry within 60 calendar days of its initiation,” the regulations provide lenience for additional time where circumstances “clearly warrant” the extension. 42 C.F.R. § 93.307(g). The institution must document the reasons for any delays in completing the inquiry in the report. Id. If the inquiry finds that there is a “reasonable basis for concluding” that there has been

research misconduct involving federal funds, 42 C.F.R. § 93.307(d)(1), and that particularized allegations of research misconduct “may have substance,” 42 C.F.R. § 93.307(d)(2), then the institution must notify both the researcher facing the inquiry and the ORI of the inquiry results within 30 days and provide a copy of the inquiry report. 42 C.F.R. § 93.309(a). After such a finding, the institution is obligated to conduct a “thorough and sufficiently documented investigation” within 120 days, absent an extension from the ORI. 42 C.F.R. §§ 93.310

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Oklahoma Press Publishing Co. v. Walling
327 U.S. 186 (Supreme Court, 1946)
United States v. Morton Salt Co.
338 U.S. 632 (Supreme Court, 1950)
Anversa v. Partners Healthcare System, Inc.
835 F.3d 167 (First Circuit, 2016)
Medici v. Lifespan Corp.
384 F. Supp. 3d 218 (D. Rhode Island, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
HOUSER v. FELDMAN, Counsel Stack Legal Research, https://law.counselstack.com/opinion/houser-v-feldman-paed-2021.